I'm not sure anybody can give you a definitive answer, but I would take an educated guess that there was an institutional investor who thinks they didn't do a good enough job at CES, or didn't launch the beta on schedule and therefore dumped their shares. In a company this small (micro) they need to be on schedule all the time. Any missteps will be painful.
The stock appears to be coming back some now, probably with the distribution of the Beta kits.
After all the pump is gone the shares will settle down to something more reasonable in the mid $20's and average investors like me can get in. No way I'm buying in the $40s.
I never said nothing happened. I said they didn't achieve progress on the primary goal. I'm sure they ran around doing lots of stuff, but they didn't hit the primary objective that was a key element of the valuation of the stock.
Since the stock has lost 2/3 of its value since its peak, so apparently the smart money agrees with me.
This management team clearly can't get the job done. Sure we've heard all the excuses about the FDA, but other companies seem to be able to make progress. SRPT cannot as is evidenced by the latest round of delays.
I wonder what their excuse will be on the next delay.
You may have jumped back in too soon. More downside (nothing to do with the company per se, but the overall China market).
BITA is going to get caught in the Great China downturn of 2015. It will simply provide a lower entry point for those of us who have been waiting to get in to BITA at the right price. May go back into the $30's. Nothing wrong with BITA, just the China leverage is overdone across the market. Then good stocks like BITA will come roaring back.
Whether it be:
1) Cheaper Product
2) Better (resolution, better compression, faster upload to web, unlimited web storage, whatever...)
3) Easier to use
This product space has quite a few similar products and consumers will need to know precisely how LifeLogger's product is BETTER.
I was also a beta tester for Google Glass - a product not quite ready for prime time just yet. I'm looking for a better product from LifeLogger with countless applications. This could be really good. Lets see if it pans out.
Another disappointment, another 15% loss at SRPT. I wonder how much lower it will go before shareholders revolt and demand new management? At $10/share? At $5/share? At some point EVERYBODY is going to figure it out.
Today's debacle comes from failure to manage expectations and just one of the many facets where management is out of touch with the investment community. They are flying blind.
Your statement is inaccurate. ISIS drugs are safe, but not yet approved. There is not a big difference in the safety profile of the NPSP drug and any from ISIS.
Another buyout, this time it is NPSP. Makes me wonder how much longer ISIS will stand alone. The value of ISIS pipeline far exceeds the $100/share upped target just announced.
Short position (Nov 28) shows 14.68M shares short versus 14.98M a month prior.
So shorts still aren't covering en masse, which means they will have to cover later, at higher prices, sending shares up even more.
In fairness, I didn't sell until after the peak of $104 and finally sold at $90 - then it went down, and is on the rebound back up now.
But my point is, they don't "all fade". Good news often builds on more good news. The more pertinent element here is that it is still very early in the game. While many may not be jumping in just yet, it has come on the radar screens of many investors now. That will always be good.
Instead of JandJ paying ISIS $835M - if they bought ISIS outright, instead of paying 1/7 for 1/31 of the drug pipeline, JandJ could buy ALL of ISIS and own the entire pipeline.
Interesting list, though for a list of "Momentum Stocks" I was surprised that the 1-month chart showed ISIS outperforming the top 6 & 14-VRTX (I didn't check the others). Makes me wonder about the parameters of a momentum list where #25 outperforms the higher ranked ones.
Not knocking it, just don't understand it.
There were several contributing factors including an overall downdraft in Biotech stocks, downward earnings (the main culprit), and competition from AEGR on Kynamro. However, the strength of the pipeline and progress payments that were delayed, came through to provide a healthy ROI.
Because ... they have changed so much over the last 30-years? Democrat, Republican, it doesn't matter, the FDA is always problemmatic. The FDA has been painfully consistent for ages. They aren't going to change. I wish they would - but they won't.
I will say it again though, other companies/management teams have been able to navigate through the FDA. SRPT is one of the ones stuck.
Since we can't change the FDA, we can only change SRPT management. Shareholders don't own the FDA, they own SRPT, so that is the only part of the equation they can change.
I never said that at all. Why invent that?
The FDA has a huge impact on the situation, but the fact of the matter is simple - SRPT Management can't work through the FDA wickets. Other companies can and have. The root of the problem here is SRPT Management.
For example, the FDA didn't force SRPT to use a ridiculously small trial sample of 12 patients - SRPT Management did. SRPT management is out of touch with the FDA. You can figure this out now, or a year from now, or 5-years from now when there still isn't a filing yet. The choice is yours.
I'd love to work for a company where shareholders give management a free pass time after time after time, with delay after delay after delay, always blaming the FDA. Eventually, shareholders figure it out. They always do & replace management. The only question is when?
Except that they cannot even FILE for approval. They can't even get out of the gate.
I am not debating the efficacy of the drug, but rather the inefficiency of management.